Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes

被引：26

作者：

Kozawa, Junji ^{[1
]}

Okita, Kohei ^{[1
]}

Imagawa, Akihisa ^{[1
]}

Iwahashi, Hiromi ^{[1
]}

Holst, Jens J. ^{[2
]}

Yamagata, Kazuya ^{[3
]}

Shimomura, Iichiro ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka, Japan

[2] Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen, Denmark

[3] Kumamoto Univ, Fac Med & Pharmaceut Sci, Dept Med Biochem, Kumamoto, Japan

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2010年 / 393卷 / 03期

关键词：

GLP-1; GIP; Diabetes; Incretin; Obese; GLUCAGON-LIKE PEPTIDE-1; GASTRIC-INHIBITORY POLYPEPTIDE; DEPENDENT INSULINOTROPIC POLYPEPTIDE; BETA-CELL MASS; GLUCOSE; HUMANS; GLP-1;

D O I：

10.1016/j.bbrc.2010.01.134

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

secretion and effect on insulin secretion are not fully understood in patients with type 2 diabetes. We investigated incretin and insulin secretion after meal intake in obese and non-obese Japanese patients with type 2 diabetes compared to non-diabetic subjects. Nine patients with type 2 diabetes and 5 non-diabetic subjects were recruited for this study. Five diabetic patients were obese (BMI >= 25) and 4 patients were non-obese (BMI < 25). In response to a mixed meal test, the levels of immunoreactive insulin during 15-90 min and C-peptide during 0-180 min in non-obese patients were significantly lower than those in obese patients. Total GLP-1 and active GIP levels showed no significant difference between obese and non-obese patients throughout the meal tolerance test. In addition, there were no significant differences between diabetic patients and non-diabetic subjects. In conclusion, incretin secretion does not differ between Japanese obese and non-obese patients with type 2 diabetes and non-diabetic subjects. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：410 / 413

页数：4

共 23 条

[1] β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes [J].

Butler, AE ;

Janson, J ;

Bonner-Weir, S ;

Ritzel, R ;

Rizza, RA ;

Butler, PC .

DIABETES, 2003, 52 (01) :102-110

[2] Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide [J].

Deacon, CF ;

Nauck, MA ;

Meier, J ;

Hücking, K ;

Holst, JJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3575-3581

[3] HYPERSECRETION OF TRUNCATED GLUCAGON-LIKE PEPTIDE-1 AND GASTRIC-INHIBITORY POLYPEPTIDE IN OBESE PATIENTS [J].

FUKASE, N ;

IGARASHI, M ;

TAKAHASHI, H ;

MANAKA, H ;

YAMATANI, K ;

DAIMON, M ;

TOMINAGA, M ;

SASAKI, H .

DIABETIC MEDICINE, 1993, 10 (01) :44-49

[4] Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes [J].

Hojberg, P. V. ;

Vilsboll, T. ;

Rabol, R. ;

Knop, F. K. ;

Bache, M. ;

Krarup, T. ;

Holst, J. J. ;

Madsbad, S. .

DIABETOLOGIA, 2009, 52 (02) :199-207

[5] The physiology of glucagon-like peptide 1 [J].

Holst, Jens Juul .

PHYSIOLOGICAL REVIEWS, 2007, 87 (04) :1409-1439

[6] Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors [J].

Holst, JJ ;

Deacon, CF .

DIABETOLOGIA, 2005, 48 (04) :612-615

[7] The influence of GLP-1 on glucose-stimulated insulin secretion -: Effects on β-cell sensitivity in type 2 and nondiabetic subjects [J].

Kjems, LL ;

Holst, JJ ;

Volund, A ;

Madsbad, S .

DIABETES, 2003, 52 (02) :380-386

[8]

KRARUP T, 1988, METABOLISM, V36, P677

[9]

LEE S, 2009, ENDOCR J, V31

[10] Functional Assessment of Pancreatic β-Cell Area in Humans [J].

Meier, Juris J. ;

Menge, Bjoern A. ;

Breuer, Thomas G. K. ;

Mueller, Christophe A. ;

Tannapfel, Andrea ;

Uhl, Waldemar ;

Schmidt, Wolfgang E. ;

Schrader, Henning .

DIABETES, 2009, 58 (07) :1595-1603

← 1 2 3 →